The objective of this study was to fabricate a novel trastuzumab-conjugated GNRs coated with porphyrin and determine whether it could selectively and effectively target as well as destroy HER2-positive breast cancers in vitro and vivo, in order to explore new strategies of treating trastuzumab-resistant breast cancers. Here, ERBB2 is linked to breast cancer.